Xu J - Search Results

1

EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon α-accelerated murine lupus.

Gallo PM, Chain RW, Xu J, Whiteman LM, Palladino A, Caricchio R, Costa-Reis P, Sullivan KE, Gallucci S. Gallo PM, et al. Among authors: xu j. Int Immunopharmacol. 2024 Oct 25;140:112692. doi: 10.1016/j.intimp.2024.112692. Epub 2024 Jul 29. Int Immunopharmacol. 2024. PMID: 39079344 Free PMC article.

2

IL-4 suppresses the responses to TLR7 and TLR9 stimulation and increases the permissiveness to retroviral infection of murine conventional dendritic cells.

Sriram U, Xu J, Chain RW, Varghese L, Chakhtoura M, Bennett HL, Zoltick PW, Gallucci S. Sriram U, et al. Among authors: xu j. PLoS One. 2014 Jan 29;9(1):e87668. doi: 10.1371/journal.pone.0087668. eCollection 2014. PLoS One. 2014. PMID: 24489947 Free PMC article.

3

STAT2 Is Required for TLR-Induced Murine Dendritic Cell Activation and Cross-Presentation.

Xu J, Lee MH, Chakhtoura M, Green BL, Kotredes KP, Chain RW, Sriram U, Gamero AM, Gallucci S. Xu J, et al. J Immunol. 2016 Jul 1;197(1):326-36. doi: 10.4049/jimmunol.1500152. Epub 2016 May 27. J Immunol. 2016. PMID: 27233962 Free PMC article.

4

TLR ligands up-regulate Trex1 expression in murine conventional dendritic cells through type I Interferon and NF-κB-dependent signaling pathways.

Xu J, Zoltick PW, Gamero AM, Gallucci S. Xu J, et al. J Leukoc Biol. 2014 Jul;96(1):93-103. doi: 10.1189/jlb.2A0713-393RR. Epub 2014 Mar 5. J Leukoc Biol. 2014. PMID: 24598055 Free PMC article.

5

Host STAT2/type I interferon axis controls tumor growth.

Yue C, Xu J, Tan Estioko MD, Kotredes KP, Lopez-Otalora Y, Hilliard BA, Baker DP, Gallucci S, Gamero AM. Yue C, et al. Among authors: xu j. Int J Cancer. 2015 Jan 1;136(1):117-26. doi: 10.1002/ijc.29004. Epub 2014 Jun 17. Int J Cancer. 2015. PMID: 24895110 Free PMC article.

6

BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion.

Jung IY, Narayan V, McDonald S, Rech AJ, Bartoszek R, Hong G, Davis MM, Xu J, Boesteanu AC, Barber-Rotenberg JS, Plesa G, Lacey SF, Jadlowsky JK, Siegel DL, Hammill DM, Cho-Park PF, Berger SL, Haas NB, Fraietta JA. Jung IY, et al. Among authors: xu j. Sci Transl Med. 2022 Nov 9;14(670):eabn7336. doi: 10.1126/scitranslmed.abn7336. Epub 2022 Nov 9. Sci Transl Med. 2022. PMID: 36350986 Free PMC article.

7

Mechanisms of resistance to CAR T cell therapies.

Singh N, Orlando E, Xu J, Xu J, Binder Z, Collins MA, O'Rourke DM, Melenhorst JJ. Singh N, et al. Among authors: xu j. Semin Cancer Biol. 2020 Oct;65:91-98. doi: 10.1016/j.semcancer.2019.12.002. Epub 2019 Dec 19. Semin Cancer Biol. 2020. PMID: 31866478 Free PMC article. Review.

8

Toward precision manufacturing of immunogene T-cell therapies.

Xu J, Melenhorst JJ, Fraietta JA. Xu J, et al. Cytotherapy. 2018 May;20(5):623-638. doi: 10.1016/j.jcyt.2017.12.007. Epub 2018 Apr 10. Cytotherapy. 2018. PMID: 29653875 Review.

9

Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities.

Xu JL, Davis MM. Xu JL, et al. Immunity. 2000 Jul;13(1):37-45. doi: 10.1016/s1074-7613(00)00006-6. Immunity. 2000. PMID: 10933393 Free article.

10

Salvage of free flaps after secondary venous ischemia by local delivery of heparin.

Kirschner RE, Xu J, Fyfe B, Chang B, Bucky LP. Kirschner RE, et al. Among authors: xu j. Ann Plast Surg. 1999 May;42(5):521-7; discussion 527-8. doi: 10.1097/00000637-199905000-00010. Ann Plast Surg. 1999. PMID: 10340861

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

66,034 results

Search Page

Filters